References
- National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington (DC): National Academies Press (US); 2011.
- Katsnelson A. Momentum grows to make ‘personalized’ medicine more ‘precise’. Nat Med. 2013;19(3):249.
- Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
- Cyranoski D. China embraces precision medicine on a massive scale. Nature. 2016;529:7584.
- Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.
- Lipshutz RJ, Fodor SP, Gingeras TR, et al. High density synthetic oligonucleotide arrays. Nat Genet. 1999;21(1 Suppl):20–24.
- McClellan J, King MC. Genetic heterogeneity in human disease. Cell. 2010;141(2):210–217.
- Wolinsky H. The thousand-dollar genome. Genetic brinkmanship or personalized medicine? EMBO Rep. 2007;8(10):900–903.
- Program) DSCDftNGS: National Human Genome Research Institute, NIH. Available from: https://www.genome.gov/sequencingcosts/
- Andreu-Perez J, Poon CCY, Merrifield RD, et al. Big data for health. IEEE J Biomed Health Inform. 2015;19(4):1193–1208.
- Andreu-Perez J, Leff DR, Ip HM, et al. From wearable sensors to smart implants–toward pervasive and personalized healthcare. IEEE Trans Biomed Eng. 2015;62(12):2750–2762.
- Signorini A, Segre AM, Polgreen PM, et al. The use of Twitter to track levels of disease activity and public concern in the U.S. during the influenza A H1N1 pandemic. PLoS One. 2011;6(5):e19467.
- Christakis NA, Fowler JH. The collective dynamics of smoking in a large social network. N Engl J Med. 2008;358(21):2249–2258.
- Larsen ME, Boonstra TW, Batterham PJ, et al. We feel: mapping emotion on Twitter. IEEE J Biomed Health Inform. 2015;19(4):1246–1252.
- Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417.
- De Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006;6(3):277–286.
- Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation. 2011;124(23):2554–2559.
- Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
- Becquemont L, Alfirevic A, Amstutz U, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB conference on pharmacogenetics and pharmacogenomics. Pharmacogenomics. 2011;12(1):113–124.
- Nicholson JK, Wilson ID, Lindon JC. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics. 2011;12(1):103–111.
- Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653–683.
- Andreev VP. Pharmacoproteomics of obesity: definitions, role and a case study of dynamics of human plasma proteome. Pharmacogenomics. 2011;12(10):1363–1365.
- Rybakowski JK, Serretti A. Genetic influences on response to drug treatment for major psychiatric disorders. Cham: Springer; 2016.
- Barh D, Dhawan D, Ganguly NK. Omics for personalized medicine. New Delhi: Springer; 2013.
- Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966–975.
- Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67(2):133–138.
- Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555–564.
- Laje G, McMahon FJ. Genome-wide association studies of antidepressant outcome: a brief review. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1553–1557.
- Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998;32(2):93–99.
- McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry. 2011;16(1):76–85.
- Gressier F, Porcelli S, Calati R, et al. Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis. Eur Neuropsychopharmacol. 2016;26(2):163–185.
- Stevenson JM, Reilly JL, Harris MS, et al. Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. Transl Psychiatry. 2016;6:e739.
- Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387(10023):1085–1093.
- Nurmi EL, Spilman SL, Whelan F, et al. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry. 2013;3:e274.
- Czerwensky F, Leucht S, Steimer W. MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol. 2013;16(9):2103–2109.
- Fan TW, Yuan P, Lane AN, et al. Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics. 2010;6(2):165–179.
- Kaddurah-Daouk R, Boyle SH, Matson W, et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry. 2011;1:e26.
- Zhu H, Bogdanov MB, Boyle SH, et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One. 2013;8(7):e68283.
- Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007;12(10):934–945.
- Malki K, Campbell J, Davies M, et al. Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. Proteomics. 2012;12(14):2355–2365.
- Mateo Leach I, van der Harst P, de Boer RA. Pharmacoepigenetics in heart failure. Curr Heart Fail Rep. 2010;7(2):83–90.
- Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. Nat Rev Neurosci. 2005;6(2):108–118.
- Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008;8(1):57–64.
- Tsankova NM, Berton O, Renthal W, et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9(4):519–525.
- Sporns O, Tononi G, Kotter R. The human connectome: a structural description of the human brain. PLoS Comput Biol. 2005;1(4):e42.
- Behrens TE, Sporns O. Human connectomics. Curr Opin Neurobiol. 2012;22(1):144–153.
- Fornito A, Bullmore ET. Connectomic intermediate phenotypes for psychiatric disorders. Front Psychiatry. 2012;3:32.
- Kochunov P, Jahanshad N, Marcus D, et al. Heritability of fractional anisotropy in human white matter: a comparison of human connectome project and ENIGMA-DTI data. Neuroimage. 2015;111:300–311.
- Whitfield-Gabrieli S, Ghosh SS, Nieto-Castanon A, et al. Brain connectomics predict response to treatment in social anxiety disorder. Mol Psychiatry. 2015;21(5):680–685.
- Rappaport SM. Implications of the exposome for exposure science. J Expo Sci Environ Epidemiol. 2011;21(1):5–9.
- Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Atlanta (GA): Centers for Disease Control and Prevention; 2010.
- Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature. 2015;526(7573):336–342.
- Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862–D868.
- Rehm HL, Berg JS, Brooks LD, et al. ClinGen–the clinical genome resource. N Engl J Med. 2015;372(23):2235–2242.
- Gottesman O, Kuivaniemi H, Tromp G, et al. The electronic medical records and genomics (eMERGE) network: past, present, and future. Genet Med. 2013;15(10):761–771.
- Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry. 2008;13(6):570–584.
- Shyn SI, Shi J, Kraft JB, et al. Novel loci for major depression identified by genome-wide association study of sequenced treatment alternatives to relieve depression and meta-analysis of three studies. Mol Psychiatry. 2011;16(2):202–215.
- Chen DT, Jiang X, Akula N, et al. Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder. Mol Psychiatry. 2013;18(2):195–205.
- Hall D, Huerta MF, McAuliffe MJ, et al. Sharing heterogeneous data: the national database for autism research. Neuroinformatics. 2012;10(4):331–339.
- Bethesda NIoHU. Adolescent Brain Cognitive Development (ABCD) Study – Research Project Sites (U01). 2015. Available from: http://grantsnihgov/grants/guide/rfa-files/RFA-DA-15-015html
- Haque R, Shi J, Schottinger JE, et al. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst. 2016;108(3):djv337.
- Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–180.
- Insel TR. The NIMH research domain criteria (RDoC) project: precision medicine for psychiatry. Am J Psychiatry. 2014;171(4):395–397.
- Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748–751.
- Karlsgodt KH. Diffusion imaging of white matter in schizophrenia: progress and future directions. Biol Psychiatry Cogn Neurosci Neuroimaging. 2015;1(3):209–217.
- Abbott A. Schizophrenia: the drug deadlock. Nature. 2010;468(7321):158–159.
- Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006;8(1):109–113.
- Klitzman R, Chung W, Marder K, et al. Attitudes and practices among internists concerning genetic testing. J Genet Couns. 2013;22(1):90–100.